Dossier assessment
Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Avelumab (Urothelkarzinom) - Nutzenbewertung gemäß § 35a SGB V
-
Dossier assessment
Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy
Indication of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2021-08-19 A G-BA decision was published.
Project details
- Project no.
- A21-23
- Commission
- Commission awarded on 18.02.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V
Status: Commission completed
-
Addendum
Avelumab (urothelial carcinoma) - Addendum to Commission A21-23
Status: Commission completed